Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 257049

Drug Profile

GSK 257049

Alternative Names: 257049; Circumsporozoite protein hepatitis-B surface antigen fusion protein- GlaxoSmithKline; CSP-HBsAg - GlaxoSmithKline; CSP-HBsAg/SBAS2-GlaxoSmithKline; FSV-1-malaria-vaccine-GlaxoSmithKline; GSK-257146; GSK-RTS,S/AS01; GSK257049; Malaria vaccine 257049 - GlaxoSmithKline; Mosquirix; Plasmodium falciparum circumsporozoite protein/HBsAg subunit vaccine - GlaxoSmithKline; Plasmodium falciparum CSP/HBsAg - GlaxoSmithKline; Plasmodium falciparum CSP/HBsAg subunit vaccine - GlaxoSmithKline; Plasmodium falciparum malaria vaccine 257049; Profilam; QS 21 stimulon adjuvanted malaria vaccine - Agenus/GlaxoSmithKline; RTS,S; RTS,S/AS; RTS,S/AS01; RTS,S/AS01B; RTS,S/AS01E; RTS,S/AS02; RTS,S/AS02A; RTS,S/AS02D; SB-257049

Latest Information Update: 03 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Malaria Vaccine Initiative; University of Oxford
  • Class Antimalarials; Parasitic vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Falciparum malaria

Most Recent Events

  • 24 Sep 2018 GlaxoSmithKline completes a phase I/II trial in Healthy volunteers in USA (IM) (NCT03162614)
  • 20 Feb 2018 PATH completes a phase-II clinical trials in Falciparum malaria (In volunteers, Combination therapy) in Thailand (IM) (NCT02992119)
  • 28 Sep 2017 GlaxoSmithKline initiates enrolment in the MALARIA-094 trial for Falciparum malaria (In infants, Prevention) in Ghana (IM) (NCT03276962)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top